C-FSZHPretzel Therapeutics
mitochondrial bioenergetics, mtDNA modulation, small molecules
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-FSZH
C-FSZHC-FSZHmitochondrial bioenergetics, mtDNA modulation, small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Pretzel Therapeutics presents mitochondrial dysfunction as a problem with genetic roots that can be addressed through a new era of mitochondrial therapeutics. The company states that it is developing treatments to reverse mitochondrial dysfunction, based on a deep mechanistic understanding of mitochondrial biology.
SourcePretzel Therapeutics states that mitochondrial dysfunction is implicated across many diseases and that this creates a major opportunity for therapeutic innovation. The company presents the belief that a deep mechanistic understanding of mitochondrial biology can be translated into groundbreaking therapies, especially for genetic mitochondrial diseases and other conditions associated with dysfunctional mitochondria.
SourcePretzel Therapeutics states that mitochondrial dysfunction is a major driver across more than 50 diseases, spanning rare genetic mitochondrial disorders and more common aging-related conditions, and that better therapies can be developed by deeply understanding and harnessing mitochondrial biology.
SourcePretzel Therapeutics states that mitochondrial dysfunction is a root cause of both rare mitochondrial diseases and broader aging-related disorders, and that first-in-class therapies aimed at the genetic drivers of this dysfunction could address it at its source across many diseases that currently lack meaningful treatment options.
Source